Vitamin D3 Supplementation in Patients With HIV: Effects on Interleukin-6 Levels and CD4 Counts

Sex: All

Ages: 19 Years – 59 Years

Healthy volunteers: No

Phase: NA

Enrollment: 20

Sponsor: Universitas Sebelas Maret

Location: Voluntary Counseling and Testing (VCT) Clinic, Dr. Moewardi General Hospital, Surakarta, Indonesia Surakarta Central Java

Summary

This study aims to evaluate the effect of Vitamin D3 supplementation on inflammatory markers and immune status in patients with HIV who are receiving antiretroviral therapy. Participants will receive Vitamin D3 supplementation for 3 months. Outcomes including Interleukin-6 levels and CD4 counts will be measured to assess the potential benefits of this intervention.

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed with HIV stage 1 or 2 who have been receiving antiretroviral therapy (ART) with a TLD regimen for at least 6 months at Dr. Moewardi General Hospital, Surakarta, Indonesia * Age 19 to 59 years * Willing to participate in the study and provide informed consent * Not currently taking any other vitamin supplements Exclusion Criteria: * Patients who discontinue treatment (dropout) or die during the study period * Patients who experience allergic reactions to Vitamin D3 supplementation

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07553052). StuddyBuddy aggregates publicly available trial information.